Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.
Orgenesis Inc (ORGS) is a global biotechnology leader pioneering decentralized cell and gene therapy manufacturing. This page provides investors and industry professionals with centralized access to official press releases, clinical trial updates, and strategic partnership announcements.
Track the latest developments in ORGS's innovative platforms, including therapeutic exosome production, automated GMP processes, and modular cleanroom deployments. Our curated news collection ensures timely updates on regulatory milestones, research breakthroughs, and operational expansions.
Key coverage areas: clinical trial progress, manufacturing partnerships, technology licensing agreements, and regulatory submissions. Bookmark this page for direct access to verified information about ORGS's advancements in immuno-oncology and regenerative medicine.
Orgenesis (Nasdaq: ORGS) has entered into a securities purchase agreement with institutional investors to sell 1,947,368 shares of common stock and warrants to purchase up to 973,684 shares at a price of $1.90 per share. The gross proceeds are estimated to be around $3.7 million before expenses. The warrants are exercisable at the same price and will expire five years after issuance. The funds from this offering are intended for working capital and general corporate purposes. The transaction is expected to close around February 27, 2023, contingent on customary conditions.
Orgenesis (NASDAQ: ORGS) and Kurve Therapeutics have announced promising results from a preclinical study demonstrating over 50% tumor reduction in a glioblastoma mouse model using intranasal delivery of a cell-based oncolytic virus. This breakthrough utilizes Kurve's Controlled Particle Dispersion® technology, overcoming the blood-brain barrier, a common challenge in CNS therapies. The study was conducted independently, and Orgenesis is equipped with clinical-grade manufacturing capabilities in partnership with Hospital Infantil Universitario Niño Jesús in Madrid, aiming for future clinical applications.
Orgenesis Inc. (NASDAQ: ORGS) announced securing up to $50 million from Metalmark Capital Partners to enhance its POCare platform. The funding, valuing the subsidiary Morgenesis LLC at $125 million, allows Orgenesis to minimize dilution. The company achieved approximately $8 million in revenue for Q3 2022 while significantly reducing operating expenses by 49%, nearing breakeven income. Orgenesis emphasizes the scalability and cost-effectiveness of its cell and gene therapy services, addressing production capacity challenges in the industry.
Orgenesis Inc (NASDAQ: ORGS) is set to host a conference call on November 11, 2022, at 8:00 AM ET to discuss its corporate progress and developments. Interested participants can join via phone or through a live webcast. The company is focused on advancing cell and gene therapies through its innovative POCare Platform, which facilitates effective and affordable treatment access. A replay of the call will be available on their Investor Events webpage after the session.
Orgenesis Inc (NASDAQ: ORGS) announced a partnership with Metalmark Capital Partners for a growth investment of up to $50 million in its US-based subsidiary, Morgenesis LLC. This investment includes an upfront $30 million, with a pre-money valuation of $125 million. The funds will be utilized to enhance Morgenesis' point-of-care services, expanding its capabilities in cell and gene therapies. Orgenesis aims to streamline POCare Services, enhancing access to innovative treatments globally.
Orgenesis Inc. (NASDAQ: ORGS) announced a $10 million loan from Metalmark Capital Partners to advance its POCare platform and point of care services. The company is transitioning to phase two of its business model, targeting revenue from process development and supply of cell and gene therapies. With over 16 clinical programs in immuno-oncology and regenerative medicine, Orgenesis aims to benefit from high-margin, recurring revenue streams. They also secured a €4M grant for personalized stem cell technologies, demonstrating significant advancements in their therapeutic pipeline.
Orgenesis Inc. (NASDAQ: ORGS) announced a conference call scheduled for August 16, 2022, at 11:00 AM ET to discuss corporate progress and developments. U.S. callers can dial 888-506-0062, while international participants can reach out at +1 973-528-0011 using entry code 223911. A webcast will also be available. Orgenesis focuses on advancing cell and gene therapies through its POCare Platform, aiming for affordable access at the point of care. A replay of the call will be accessible via the company's Investor Events section until August 16, 2023.
Orgenesis Inc. (NASDAQ: ORGS) reported a business update for Q1 2022, highlighting significant advancements in its POCare Platform. Key developments include the expansion of POCare partnerships with Johns Hopkins University and Hospital Infantil Universitario Niño Jesús, alongside securing a €4M grant from the European Innovation Council. CEO Vered Caplan emphasized the company's ongoing rollout and its potential for significant revenue from long-term contracts for clinical trials. The existing contract pipeline suggests a potential revenue exceeding $75 million in two years, indicating promising growth.
Orgenesis Inc. (NASDAQ: ORGS) has received a €4 million grant from the European Innovation Council Pathfinder Challenge Program. This funding will support the development of cost-effective production technologies for autologous induced pluripotent stem cells (iPSCs) using microfluidic technologies and AI. The initiative, led by MIDA Biotech, aims to enhance the speed and affordability of producing personalized iPSCs, addressing current manufacturing challenges. The project is expected to speed iPSC production while significantly reducing costs, potentially unlocking new therapies in regenerative medicine.
Orgenesis Inc. (NASDAQ: ORGS) has entered into a definitive agreement for a private placement of 4,933,333 shares at $3.00 each, alongside warrants for 1,000,000 shares at $4.50. Gross proceeds are expected to be approximately $14.8 million, with closing anticipated around April 30, 2022. The securities will be sold under Regulation D and are not registered under the Securities Act. The company aims to file a registration statement for the resale of the shares and warrants. Orgenesis focuses on cell and gene therapies through its POCare Platform.
FAQ
What is the current stock price of Orgenesis (ORGS)?
What is the market cap of Orgenesis (ORGS)?
